Tukysa: Warnings & Precautions

The therapeutic product Tukysa, containing the active substance Tucatinib, is a film-coated tablet that falls under the classification of tyrosine kinase inhibitors. Tukysa is commercially supplied as a 150 mg or 50 mg film-coated tablet. Seattle Genetics is credited for the medicine development and efforts in securing regulatory approval. 

Tukysa is a relatively new therapeutic product yet to be authorized in several world regions, including India. Tukysa cost in India depends on its availability and the regulatory constraints noted by the country of import.

Tukysa has been approved with trastuzumab and capecitabine to treat adult individuals with unresectable or metastatic HER2+ breast cancer, including those with brain metastases regimens previously treated with one or more anti-HER2-based.

The medicine is also authorized in conjunction with medicine trastuzumab to treat adult individuals with RAS wild-type HER2+ unresectable or metastatic colorectal cancer that has proceeded after treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.

Tukysa is available on prescription only. The recommended dosage of Tukysa tablets is 300 mg, taken orally twice daily in 21-day cycles. 

Warnings and Precautions:

Diarrhea: The medication Tukysa can be responsible for causing severe diarrhea, including hypotension, 

dehydration, and acute kidney injury. In case diarrhea is reported, administer anti-diarrheal medicines. Perform diagnostic tests to exclude other potential causes of diarrhea. On behalf of the seriousness of diarrhea, doses can be interrupted, scaled down, or permanently stopped.

Hepatotoxicity: This therapeutic product can be responsible for causing severe hepatotoxicity. Monitor AST, ALT, and bilirubin before treatment and every 3 weeks during treatment. On behalf of the severity of hepatotoxicity, Tucatinib doses can be interrupted, scaled down, or permanently stopped.

Embryo-Fetal Toxicity: This tyrosine kinase inhibitor can cause fetal harm. Instruct pregnant women and women of reproductive age about the probable hazard to a fetus. Females of reproductive capacity and male patients with female partners of reproductive age should use suitable contraception during Tukysa therapy and at least 7 days after the eventual dose.

Note: The price of Tukysa is economical and one can order this medicine from multiple pharmaceutical suppliers in India. 

Reference: https://www.seagen.com/medicines/tukysa